Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
November 25, 2024 16:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
November 07, 2024 16:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
November 07, 2024 08:10 ET
|
Third Harmonic Bio
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
September 10, 2024 16:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio to Participate in Upcoming Investor Conferences
August 26, 2024 16:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 08:05 ET
|
Third Harmonic Bio
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $255.3...
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
May 28, 2024 16:05 ET
|
Third Harmonic Bio
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 08:05 ET
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
March 28, 2024 08:30 ET
|
Third Harmonic Bio
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
March 26, 2024 08:05 ET
|
Third Harmonic Bio
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO,...